• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吲哚、苯并咪唑和噻吩并吡咯衍生的组胺 H4 受体配体的反向激动和中性拮抗的结构要求。

Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.

机构信息

Departments of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany.

出版信息

J Pharmacol Exp Ther. 2010 Aug;334(2):513-21. doi: 10.1124/jpet.110.165977. Epub 2010 May 18.

DOI:10.1124/jpet.110.165977
PMID:20484153
Abstract

The human histamine H(4) receptor (hH(4)R), coexpressed with Galpha(i2) and Gbeta(1)gamma(2) in Sf9 insect cells, is highly constitutively active, and thioperamide [THIO; N-cyclohexyl-4-(imidazol-4-yl)-1-piperidinecarbothioamide] is one of the most efficacious hH(4)R inverse agonists. High constitutive hH(4)R activity may have pathophysiological implications in which case inverse agonists may behave differently than neutral antagonists. To learn more about the structural requirements for hH(4)R inverse agonism, we investigated 25 compounds (indole, benzimidazole, and thienopyrrole derivatives) structurally related to the standard antagonist JNJ-7777120 [1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methyl-piperazine]. We characterized the compounds in radioligand binding assays by using [(3)H]histamine ([(3)H]HA) and in steady-state GTPase assays in the presence (antagonist mode) and absence (inverse agonist mode) of the agonist HA, yielding the following results: 1) Twenty-two compounds were inverse agonists (efficacy: 15-62% of the THIO effect), and only three compounds (12%) showed neutral antagonism. Thus, inverse agonism is far more common than neutral antagonism. 2) The inverse agonistic efficacy of the R5-monosubstituted indole-derived compounds increased with the volume of R5. R5 may interact with Trp(6.48) of the rotamer toggle switch and stabilize the inactive receptor conformation. 3) A subset of compounds showed large differences between the K(i) value from [(3)H]HA competition binding and the EC(50) value from steady-state GTPase assays, whereas the K(b) values were closer to the K(i) values. Thus, the two-state model should be extended to a model comprising a constitutively active hH(4)R state, which can be discriminated by inverse agonists from a structurally distinct HA-stabilized active state.

摘要

人源组氨酸 H(4) 受体(hH(4)R)与 Sf9 昆虫细胞中的 Galpha(i2) 和 Gbeta(1)gamma(2) 共表达,具有高度组成型活性,噻哌酰胺(THIO;N-环己基-4-(咪唑-4-基)-1-哌啶甲硫酰胺)是最有效的 hH(4)R 反向激动剂之一。高组成型 hH(4)R 活性可能具有病理生理学意义,在这种情况下,反向激动剂的行为可能与中性拮抗剂不同。为了更多地了解 hH(4)R 反向激动作用的结构要求,我们研究了 25 种化合物(吲哚、苯并咪唑和噻吩并吡咯衍生物),这些化合物与标准拮抗剂 JNJ-7777120 [1-[(5-氯-1H-吲哚-2-基)羰基]-4-甲基-哌嗪]在结构上相关。我们通过使用 [(3)H]组胺 ([(3)H]HA) 在放射性配体结合测定中和在激动剂 HA 的存在(拮抗剂模式)和不存在(反向激动剂模式)下在稳态 GTPase 测定中对化合物进行了表征,得出以下结果:1) 22 种化合物是反向激动剂(效力:THIO 作用的 15-62%),只有 3 种化合物(12%)表现出中性拮抗作用。因此,反向激动作用远比中性拮抗作用常见。2) R5-取代的吲哚衍生化合物的反向激动效力随 R5 的体积增加而增加。R5 可能与旋转开关的 Trp(6.48)相互作用并稳定非活性受体构象。3) 一组化合物在 [(3)H]HA 竞争结合的 K(i) 值和稳态 GTPase 测定的 EC(50) 值之间表现出很大差异,而 K(b) 值更接近 K(i) 值。因此,二态模型应扩展到包括一个组成型激活的 hH(4)R 状态的模型,该状态可以通过反向激动剂与结构上不同的 HA 稳定的活性状态区分开来。

相似文献

1
Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.吲哚、苯并咪唑和噻吩并吡咯衍生的组胺 H4 受体配体的反向激动和中性拮抗的结构要求。
J Pharmacol Exp Ther. 2010 Aug;334(2):513-21. doi: 10.1124/jpet.110.165977. Epub 2010 May 18.
2
Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor.组胺H1受体激动剂和拮抗剂与人组胺H4受体的相互作用。
Mol Pharmacol. 2009 Nov;76(5):1019-30. doi: 10.1124/mol.109.058651. Epub 2009 Aug 31.
3
High constitutive activity and a G-protein-independent high-affinity state of the human histamine H(4)-receptor.人类组胺H(4)受体的高组成活性和不依赖G蛋白的高亲和力状态。
Biochemistry. 2009 Feb 17;48(6):1424-38. doi: 10.1021/bi802050d.
4
Role of the second and third extracellular loops of the histamine H(4) receptor in receptor activation.组胺 H(4)受体第二和第三细胞外环在受体激活中的作用。
Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):301-17. doi: 10.1007/s00210-011-0673-3. Epub 2011 Jul 29.
5
N (α)-Methylated phenylhistamines exhibit affinity to the hH(4)R-a pharmacological and molecular modelling study.N(α)-甲基苯海拉明对 hH(4)R 具有亲和力:药理学和分子建模研究。
Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):287-99. doi: 10.1007/s00210-011-0671-5. Epub 2011 Jul 29.
6
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.人组胺H4受体上组胺H1、H2和H3受体配体的评估:4-甲基组胺作为首个强效且选择性H4受体激动剂的鉴定。
J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21. doi: 10.1124/jpet.105.087965. Epub 2005 Jun 9.
7
Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.一系列 2-芳基苯并咪唑 H4 受体配体中的激动剂/拮抗剂调节。
Bioorg Med Chem Lett. 2010 Jun 1;20(11):3367-71. doi: 10.1016/j.bmcl.2010.04.017. Epub 2010 Apr 11.
8
2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.2,4-二氨基嘧啶作为组胺H1和H4受体的双重配体——H1/H4受体选择性
Bioorg Med Chem Lett. 2016 Jan 15;26(2):292-300. doi: 10.1016/j.bmcl.2015.12.035. Epub 2015 Dec 11.
9
Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.吲哚和苯并咪唑哌嗪类组胺H(4)受体拮抗剂的合成及其构效关系
Bioorg Med Chem Lett. 2004 Nov 1;14(21):5251-6. doi: 10.1016/j.bmcl.2004.08.035.
10
Profiling of histamine H4 receptor agonists in native human monocytes.在原代人单核细胞中鉴定组氨酸 H4 受体激动剂。
Br J Pharmacol. 2013 Sep;170(1):136-43. doi: 10.1111/bph.12237.

引用本文的文献

1
Inhibiting a promiscuous GPCR: iterative discovery of bitter taste receptor ligands.抑制混杂 GPCR:苦味受体配体的反复发现。
Cell Mol Life Sci. 2023 Apr 3;80(4):114. doi: 10.1007/s00018-023-04765-0.
2
Pharmacological Characterization of Human Histamine Receptors and Histamine Receptor Mutants in the Sf9 Cell Expression System.人组胺受体及组胺受体突变体在 Sf9 细胞表达系统中的药理学特性研究
Handb Exp Pharmacol. 2017;241:63-118. doi: 10.1007/164_2016_124.
3
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.
国际基础与临床药理学联合会。XCVIII.组胺受体。
Pharmacol Rev. 2015 Jul;67(3):601-55. doi: 10.1124/pr.114.010249.
4
Pharmacological profile of astemizole-derived compounds at the histamine H1 and H4 receptor--H1/H4 receptor selectivity.阿司咪唑衍生化合物在组胺 H1 和 H4 受体上的药理学特性--H1/H4 受体选择性。
Naunyn Schmiedebergs Arch Pharmacol. 2014 Mar;387(3):235-50. doi: 10.1007/s00210-013-0926-4. Epub 2013 Nov 17.
5
Molecular and cellular analysis of human histamine receptor subtypes.人类组胺受体亚型的分子和细胞分析。
Trends Pharmacol Sci. 2013 Jan;34(1):33-58. doi: 10.1016/j.tips.2012.11.001. Epub 2012 Dec 17.
6
Small molecules with similar structures exhibit agonist, neutral antagonist or inverse agonist activity toward angiotensin II type 1 receptor.具有相似结构的小分子对血管紧张素 II 型 1 受体表现出激动剂、中性拮抗剂或反向激动剂活性。
PLoS One. 2012;7(6):e37974. doi: 10.1371/journal.pone.0037974. Epub 2012 Jun 14.
7
Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials.基于结构的预测组胺 H3 受体选择性拮抗剂在临床试验中的亚型选择性。
J Chem Inf Model. 2011 Dec 27;51(12):3262-74. doi: 10.1021/ci200435b. Epub 2011 Nov 16.
8
Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics.重组人源组胺 H₁R、H₂R、H₃R 和 H₄R 受体与 34 种抗抑郁药和抗精神病药的相互作用。
Naunyn Schmiedebergs Arch Pharmacol. 2012 Feb;385(2):145-70. doi: 10.1007/s00210-011-0704-0. Epub 2011 Oct 28.
9
N (α)-Methylated phenylhistamines exhibit affinity to the hH(4)R-a pharmacological and molecular modelling study.N(α)-甲基苯海拉明对 hH(4)R 具有亲和力:药理学和分子建模研究。
Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):287-99. doi: 10.1007/s00210-011-0671-5. Epub 2011 Jul 29.
10
Role of the second and third extracellular loops of the histamine H(4) receptor in receptor activation.组胺 H(4)受体第二和第三细胞外环在受体激活中的作用。
Naunyn Schmiedebergs Arch Pharmacol. 2011 Sep;384(3):301-17. doi: 10.1007/s00210-011-0673-3. Epub 2011 Jul 29.